The Chemo-Gut Trial: A double-blind randomized controlled trial investigating the effects of a multi-strain probiotic on gut microbiota, gastrointestinal symptoms, and psychosocial health in cancer survivors

化学肠道试验：一项双盲随机对照试验，研究多菌株益生菌对癌症幸存者肠道微生物群、胃肠道症状和心理社会健康的影响

• 批准号: 472129
• 负责人: Deleemans Julie
• 金额: $ 9.83万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-10-01 至 2025-10-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472129&lang=en
• 关键词: Cancer Survivorship; Gastrointestinal Health; Gut Microbiota; Patient Reported Outcomes; Probiotics; Psychosocial Health

Background: For select cancers (e.g. leukemia, breast) 5-year survival rates range from 61 - 89% but many survivors will experience chronic symptoms after treatment ends. Our previous work shows that 52% of survivors experience moderate to severe gastroin

背景：对于特定的癌症(如白血病、乳腺癌)，5年生存率在61%-89%之间，但许多幸存者在治疗结束后会出现慢性症状。我们之前的工作表明，52%的幸存者经历了中度到重度的胃痛